ZMC(600216)2025-01-22 09:55Financial Performance Forecast - Zhejiang Medicine Co., Ltd. expects a net profit attributable to shareholders for 2024 to be between CNY 1,039 million and CNY 1,246 million, an increase of CNY 609 million to CNY 816 million compared to the previous year, representing a year-on-year growth of 141.83% to 190.01%[2] - The company anticipates a net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 to be between CNY 1,040 million and CNY 1,248 million, an increase of CNY 886 million to CNY 1,095 million compared to the previous year, reflecting a year-on-year increase of 578.41% to 714.09%[3] - In 2023, the total profit was CNY 363 million, with a net profit attributable to shareholders of CNY 429 million, and a net profit after deducting non-recurring gains and losses of CNY 153 million[4] - The earnings per share for 2023 was CNY 0.45[5] Growth Drivers - The main drivers for the expected profit increase in 2024 include advancements in technology, optimization of product series, and adjustments in production capacity within the life nutrition segment, leading to significant growth in sales revenue of key products[6] - The company remains committed to its core development strategy, leveraging national policies on biomedicine and health as significant growth opportunities[6] Market Strategy and Challenges - The company emphasizes the necessity of cost reduction, efficiency improvement, product structure adjustment, and differentiation to navigate market challenges[6] Forecast Validity - The performance forecast has not been audited by registered accountants, and there are no significant uncertainties affecting the accuracy of the forecast[7] - The forecast data is preliminary and subject to change, with final figures to be disclosed in the audited 2024 annual report[8]